Bernard M. Fine

3.6k total citations
39 papers, 2.2k citations indexed

About

Bernard M. Fine is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Bernard M. Fine has authored 39 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 14 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Bernard M. Fine's work include HER2/EGFR in Cancer Research (8 papers), Prostate Cancer Treatment and Research (8 papers) and Medical Imaging Techniques and Applications (5 papers). Bernard M. Fine is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Prostate Cancer Treatment and Research (8 papers) and Medical Imaging Techniques and Applications (5 papers). Bernard M. Fine collaborates with scholars based in United States, Australia and Netherlands. Bernard M. Fine's co-authors include Lukas C. Amler, Andrea Pirzkall, Pieter R. Cullis, M. Bloom, Michel Lafleur, Elizabeth A. Punnoose, Siminder Atwal, Mark R. Lackner, Edward Sternin and Rodney J. Hicks and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Physical Review Letters and The Journal of Chemical Physics.

In The Last Decade

Bernard M. Fine

39 papers receiving 2.2k citations

Peers

Countries citing papers authored by Bernard M. Fine

Since Specialization

Citations

This map shows the geographic impact of Bernard M. Fine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernard M. Fine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernard M. Fine more than expected).

Fields of papers citing papers by Bernard M. Fine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernard M. Fine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernard M. Fine. The network helps show where Bernard M. Fine may publish in the future.

Co-authorship network of co-authors of Bernard M. Fine

This figure shows the co-authorship network connecting the top 25 collaborators of Bernard M. Fine. A scholar is included among the top collaborators of Bernard M. Fine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernard M. Fine. Bernard M. Fine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma 2020 ·Blood ·Adam D. Cohen, Simon J. Harrison, Amrita Krishnan, Rafaël Fonseca, Peter A. Forsberg, Andrew Spencer, Jesús G. Berdeja, Jacob P. Laubach, (unknown), Voleak Choeurng, Anjali Vaze, Divya Samineni, Teiko Sumiyoshi, James Cooper, Bernard M. Fine, Suzanne Trudel	65
2	Clinical pharmacology of vc-MMAE antibody–drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies 2019 ·mAbs ·Chunze Li, Cindy Zhang, Zao Li, Divya Samineni, Dan Lu, Bei Wang, (unknown), (unknown), Priya Agarwal, Bernard M. Fine, Sandhya Girish	41
3	Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using⁸⁹Zr-DFO-MSTP2109A Anti-STEAP1 Antibody 2019 ·Journal of Nuclear Medicine ·Jorge A. Carrasquillo, Bernard M. Fine, Neeta Pandit‐Taskar, Steven M. Larson, Stephen E. Fleming, Josef J. Fox, Sarah M. Cheal, Joseph A. O’Donoghue, Shutian Ruan, Govind Ragupathi, Serge K. Lyashchenko, John L. Humm, Howard I. Scher, Mithat Gönen, Simon P. Williams, Daniel C. Danila, Michael J. Morris	42
4	Time‐to‐Event Modeling of Peripheral Neuropathy: Platform Analysis of Eight Valine‐Citrulline‐Monomethylauristatin E Antibody–Drug Conjugates 2019 ·CPT Pharmacometrics & Systems Pharmacology ·Matts Kågedal, Divya Samineni, William R. Gillespie, Dan Lu, Bernard M. Fine, Sandhya Girish, Chunze Li, Jin Y. Jin	12
5	Platform model describing pharmacokinetic properties of vc-MMAE antibody–drug conjugates 2017 ·Journal of Pharmacokinetics and Pharmacodynamics ·Matts Kågedal, Leonid Gibiansky, Jian Xu, Xin Wang, Divya Samineni, (unknown), Dan Lu, Priya Agarwal, Bei Wang, Ola M. Saad, Neelima Koppada, Bernard M. Fine, Jin Y. Jin, Sandhya Girish, Chunze Li	9
6	Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic 2016 ·Regulatory Toxicology and Pharmacology ·Nicola J. Stagg, Ben‐Quan Shen, Flávia Brunstein, Chunze Li, Amrita V. Kamath, Fiona Zhong, Melissa M. Schutten, Bernard M. Fine	34
7	ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment 2015 ·Clinical Cancer Research ·Laetitia E. Lamberts, C. Willemien Menke‐van der Houven van Oordt, (unknown), Frederike Bensch, (unknown), Johannes Voortman, Otto S. Hoekstra, Simon P. Williams, Bernard M. Fine, Daniel Maslyar, Johan R. de Jong, Jourik A. Gietema, Carolien P. Schröder, Alphons H.H. Bongaerts, Marjolijn N. Lub–de Hooge, Henk M.W. Verheul, Sandra Sanabria Bohórquez, Andor W.J.M. Glaudemans, Elisabeth G.E. de Vries	77
8	Abstract 4310: Predictive biomarkers of tumor sensitivity to STEAP1 antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) 2015 ·Cancer Research ·Daniel C. Danila, Howard I. Scher, Edith Szafer‐Glusman, (unknown), (unknown), Martin Fleisher, Nicole A. Schreiber, Kristen Curtis, Houston Gilbert, Daniel Maslyar, Bernard M. Fine, Ron Firestein, Michael Mamounas, Mark R. Lackner, Omar Kabbarah	1
9	STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC). 2015 ·Journal of Clinical Oncology ·Daniel C. Danila, Martin Fleisher, Jorge A. Carrasquillo, Houston Gilbert, Michael J. Morris, (unknown), (unknown), Edith Szafer‐Glusman, (unknown), Chintan Patel, Nicole A. Schreiber, Kristen Curtis, Daniel Maslyar, Vanessa Lemahieu, Bernard M. Fine, Michael Mamounas, Alexander Ungewickell, Mark R. Lackner, Howard I. Scher, Omar Kabbarah	4
10	Pertuzumab and Erlotinib in Patients With Relapsed Non-Small Cell Lung Cancer: A Phase II Study Using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging 2014 ·The Oncologist ·Brett Hughes, Linda Mileshkin, P. Townley, Barbara J. Gitlitz, Keith D. Eaton, Paul Mitchell, Rodney J. Hicks, Katie Wood, (unknown), Bernard M. Fine, (unknown), Andrea Pirzkall	19
11	Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib 2012 ·Clinical Cancer Research ·Elizabeth A. Punnoose, Siminder Atwal, Weiqun Liu, Rajiv Raja, Bernard M. Fine, Brett Hughes, Rodney J. Hicks, Garret M. Hampton, Lukas C. Amler, Andrea Pirzkall, Mark R. Lackner	341
12	Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib 2011 ·Clinical Cancer Research ·Linda Mileshkin, Rodney J. Hicks, Brett Hughes, Paul Mitchell, Veena Charu, Barbara J. Gitlitz, David Macfarlane, Benjamin Solomon, Lukas C. Amler, Wei Yu, Andrea Pirzkall, Bernard M. Fine	106
13	Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer 2011 ·European Journal of Nuclear Medicine and Molecular Imaging ·(unknown), David Binns, Andrea Pirzkall, Wei Yu, Jason Callahan, Linda Mileshkin, Peter S. Conti, Andrew M. Scott, David Macfarlane, Bernard M. Fine, Rodney J. Hicks	26
14	Decision Making for a Companion Diagnostic in an Oncology Clinical Development Program 2011 ·Drug Information Journal ·Lee D. Kaiser, Claus Becker, (unknown), Bernard M. Fine	4
15	Development of a microarray platform for FFPET profiling: application to the classification of human tumors 2009 ·Journal of Translational Medicine ·Sven Duenwald, Mingjie Zhou, Yanqun Wang, Serguei Lejnine, Amit Kulkarni, (unknown), Ryan Smith, John C. Castle, George Tokiwa, Bernard M. Fine, Hongyue Dai, Thomas L. Fare, Matthew J. Marton	14
16	A Cell Proliferation Signature Is a Marker of Extremely Poor Outcome in a Subpopulation of Breast Cancer Patients 2005 ·Cancer Research ·Hongyue Dai, Laura van’t Veer, John R. Lamb, Yudong D. He, Mao Mao, Bernard M. Fine, René Bernards, Marc J. van de Vijver, Paul Deutsch, Alan B. Sachs, Roland Stoughton, Stephen Friend	207
17	Dynamic Critical Phenomena in Aqueous Protein Solutions 1995 ·Physical Review Letters ·Bernard M. Fine, Jayanti Pande, Aleksey Lomakin, Olutayo Ogun, George B. Benedek	31
18	Comparison of the orientational order of lipid chains in the L.alpha. and HII phases 1990 ·Biochemistry ·Michel Lafleur, Pieter R. Cullis, Bernard M. Fine, M. Bloom	48
19	Smoothed orientational order profile of lipid bilayers by 2H-nuclear magnetic resonance 1989 ·Biophysical Journal ·Michel Lafleur, Bernard M. Fine, Edward Sternin, Pieter R. Cullis, M. Bloom	212
20	Acyl chain orientational order in the hexagonal HII phase of phospholipid-water dispersions 1988 ·Biophysical Journal ·Edward Sternin, Bernard M. Fine, M. Bloom, Colin Tilcock, (unknown), Pieter R. Cullis	58

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact